Clinical Trials Logo

MDR-TB clinical trials

View clinical trials related to MDR-TB.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05493267 Recruiting - Immunotherapy Clinical Trials

A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

Start date: August 3, 2022
Phase: Phase 4
Study type: Interventional

A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.

NCT ID: NCT05278988 Recruiting - MDR-TB Clinical Trials

A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB

Start date: April 1, 2021
Phase: Phase 4
Study type: Interventional

This is an exploratory, prospective, randomized, active control, and open label clinical trial to evaluate the efficacy and safety of 6-9 months treatment with the ultrashort PRS Regimen V.

NCT ID: NCT05175794 Recruiting - Tuberculosis Clinical Trials

Triage Test for All Oral DR-TB Regimen (TRiAD Study)

Start date: May 26, 2022
Phase:
Study type: Observational

A Phase 4 operational study to assess the effectiveness, feasibility, acceptability, and cost effectiveness of the GeneXpert MTB/XDR (Xpert XDR; Cepheid) assay for rapid triage-and-treatment of DR-TB-A multi-centre, multi-country prospective cohort study

NCT ID: NCT03069534 Recruiting - MDR TB Clinical Trials

Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB

rhIL-2
Start date: June 1, 2009
Phase: Phase 2/Phase 3
Study type: Interventional

Multidrug-resistant tuberculosis (MDR-TB) has emerged as a challenge worldwide. Few studies have prospectively reported outcomes in patients with pulmonary MDR-TB treated with adjunctive immunotherapy combined to standard chemotherapy. We aimed to assess whether immunotherapy with Interleukin(IL)-2 enhanced the clinical and immune effects of treatment on MDR-TB patients.We performed a multicentre prospective cohort study extend all over Jiangsu province in China. Two groups were generated based on the adjunctive rhIL-2 therapy during 24 months regiman. Bacteriological and imaging data were followed during 24 months with cure rates analysed.